FDG PET/CT Predicts Stem Cell Transplant Response in Lymphoma
Lesions detected by FDG PET/CT can predict success of stem cell transplant in patients with aggressive lymphoma.
Imaging with FDG PET/CT among patients with aggressive lymphoma can help predict response to stem cell transplant, according to a study published in Radiology.
Researchers from Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College in New York, NY, performed a retrospective review study to determine the prognostic value of performing FDG PET/CT before allogeneic and autologous stem cell transplantation (SCT) in patients with aggressive lymphoma.
One-hundred-seventy-five patients with aggressive lymphoma who underwent allogeneic or autologous SCT between January 2005 and December 2010 participated in the study. The FDG PET/CT imaging of between mid-skull and upper thigh was performed within the three-month period before the transplantation; 73 patients underwent FDG PET/CT before [[{"type":"media","view_mode":"media_crop","fid":"44068","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_90076324399","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4904","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 120px; width: 160px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":" ","typeof":"foaf:Image"}}]]allogeneic SCT and 102 patients underwent FDG PET/CT before autologous SCT. The researchers evaluated the PET/CT images for lesions with FDG avidity greater than that of the background liver.
The results showed that before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions.
Two-year progression-free survival:
“Similar differences were seen in overall survival and disease-specific survival,” the authors wrote. “The risk for post-transplantation recurrence correlated with higher lesional maximum standardized uptake values: for PFS, P < .0001 to P = .01; for DSS, P < .0001 to P = .002; and for OS, P < .0001 to P = .015.”
The researchers concluded that performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic value and gives physicians a better indication of the likelihood of SCT success.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
